In terms of Regulation 33 read with Regulation 30 of the Securities and Exchange Board of . India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the ''Listing Regulations''), we wish to inform you that the Unaudited Financial Results (Standalone) of the Company for the Quarter and Half-Year ended September 30, 2018 were approved by the Board of Directors of the Company at its meeting held today.

Kappac Pharma Ltd. provides specialty pharmaceutical products. The Company offers generic drugs, medicinal, and botanical drug delivery technologies. Kappac Pharma operates in India.

Submission Of Audited Financial Result For Quarter And Half-Year Ended September 30,2018 Pursuant To Regulation 33 Of The Sebi (Lodr) Regulations, 2015

As per "Code of Internal Procedure and Conduct for Prevention of Insider Trading" in Shares of the Company ("Code"), the trading window will remain closed from October 29, 2018 to November 03, 2018 (both days Inclusive) in connection with the announcement of the UnAudited financial results of the company for quarter ending September 30, 2018 for Directors and other employees of the Company covered under the Code. The trading window will reopen on November 06, 2018.

Closure Of Trading Window

KAPPAC PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2018 ,inter alia, to consider and approve As per "Code of Internal Procedure and Conduct for Prevention of Insider Trading" in Shares of the Company ("Code"), the trading window will remain closed from October 29, 2018 to November 03, 2018 (both days Inclusive) in connection with the announcement of the UnAudited ....

Board Meeting Intimation For Compliance Of Regulation 29 Of Sebi (Lodr) , Regulations, 2015

With reference to the above, please find enclosed Certificate under Regulation 40(9) of SEBI(Listing Obligation and Disclosure Requirements) Regulation, 2015 of the Company for thequarter ended 30.09.2018.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Kappac Pharma (KPH IN)

Submission Of Audited Financial Result For Quarter And Half-Year Ended September 30,2018 Pursuant To Regulation 33 Of The Sebi (Lodr) Regulations, 2015

Submission Of Audited Financial Result For Quarter And Half-Year Ended September 30,2018 Pursuant To Regulation 33 Of The Sebi (Lodr) Regulations, 2015

Closure Of Trading Window

Board Meeting Intimation For Compliance Of Regulation 29 Of Sebi (Lodr) , Regulations, 2015

Submission Of Certificate Under Regulation 40 (9} Of Sebi (Listing Obligation And Disclosure Requirements) Regulation, 2015

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)